Latest News – Over 5 million euros for Lindis Blood Care: development of a new product for…

A Targeted Approach

Blood Transfusions (BT) are indicated when a patient is loosing more than 0,5 L blood. This can be the case in the event of significant blood loss due to surgery. Intraoperative Blood Salvage (IBS) is a technique that is frequently used in major blood loss surgery (liver, renal ..) to reduce or avoid allogenic red blood cell transfusion and the associated risks and costs. Blood becomes more and more a rare good, surgeries are being cancelled due to the lack of blood.

Autologous salvaged blood has the benefit that it

  • does not result in immunological challenge and associated safety issues,

  • provides a higher quality red blood cell and

  • avoid the risk of acquired virus infections

Blood salvage and transfusion is common in severe surgeries but so far not in cancer due to cancer cells in the shed blood.

Our Solution

Lindis Blood Care has started a project to develop a Medical Device, to remove the cancer cells out of the blood that is collected during the surgery.

This would enable the physician to remove cancer cells from blood during cancer surgeries and – as a result – make Autologous Blood Transfusion possible.

Therefore, we use a patented technology based on a trivalent antibody and equipment which is currently available at nearly all hopitals.

Advantages

Autologous Blood Salvage has great advantages over allogenic blood.

  • In contrast to allogenic blood, the patient’s type of blood is instantly available and requires no cross matching

  • No downregulation of the immune system resulting in patients better chance to survive

  • Leads to a higher rate of successful cancer treatments

Risk Reduction for tumor patients and physicians

  • No risk of transfusion reactions due to incompatibility

  • No risk of transmitted disease, such as Hepatitis, CMV, HIV, etc.

  • Reduction of wound infections

Pharmacoeconomics

  • Cost-effective compared to fully burdened allogenic blood transfusion

  • No costs for treatment of the severe side effects of allogenic blood transfusions

Risk Reduction for Tumor Patients and Physicians

0%

No risk of transfusion reactions due to incompatibility

0%

No risk of transmitted disease, such as Hepatitis, CMV, HIV, etc.

0%

No downregulation of patients immune system

Learn about our Business Model

“Blood is a rare good. Providing all people with their own purified blood, when they need it urgently, cleaned from cancer cells directly in the operating room, is what we do. To do so globally is our goal

Franzpeter Bracht, Founder & Investor

Investor Relations

Seed financing was signed by Bracht Beteiligungsgesellschaft mbH (BBG) in Feb 2018.

The Next Step in
Blood Management

CATUVAB – a MEDIVAL DEVICE to remove cancer cells from blood.

Contact Us